Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1670385

registered interest
date	15/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Tumours: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether NICE assessments of rare tumour type treatments consider both the failure rate of radiotherapy and the success rate of new treatments.
tabling member constituency	North East Hampshire
tabling member printed	Mr Ranil Jayawardena
uin	2190
answer	answer is ministerial correction date of answer 20/11/2023 answer text <p>In its evaluations of new health technologies, including for rare diseases, the National Institute for Health and Care Excellence (NICE) takes into account all health-related costs and benefits, including evidence of comparative outcomes against existing treatment options such as radiotherapy. Full details of the process and methods used by NICE in undertaking evaluations are set out in NICE health technology evaluations: the manual, published on the NICE website and available at the following link:</p><p><a href="https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nice.org.uk%2Fprocess%2Fpmg36%2Fchapter%2Fintroduction-to-health-technology-evaluation&amp;data=05%7C01%7CMD.Support%40dhsc.gov.uk%7C333109cf26904e79aba608dbe7825f03%7C61278c3091a84c318c1fef4de8973a1c%7C1%7C0%7C638358319347196670%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=hNltwwubSKJyLzQAyiKcpnHhf45seq1SehLv59TkbCo%3D&amp;reserved=0" target="_blank">https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 20/11/2023 16:42:51 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4498 label Biography information for Mr Ranil Jayawardena

1670388

registered interest
date	15/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will take steps to ensure non-stageable cancers are included in the NHS early diagnosis target.
tabling member constituency	North East Hampshire
tabling member printed	Mr Ranil Jayawardena
uin	2191
answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>The NHS Long Term Plan set an ambition that, by 2028, the proportion of cancers diagnosed at stages 1 and 2 will rise from around half now to three-quarters of cancer patients. Achieving this will mean that, from 2028, 55,000 more people each year will survive their cancer for at least five years after diagnosis. Due to the nature of the ambition, this only includes stageable cancers.</p><p>To find and diagnosed all cancers earlier, NHS England is streamlining cancer pathways to support diagnosis within 28 days by implementing non-symptom specific (NSS) pathways for patients who present with non-specific symptoms that can indicate several cancers, as well as implementing timed cancer pathways.</p><p>Since 2019, cancer alliances have been developing new dedicated urgent diagnostic pathways for these patients so that every cancer patient with concerning, but non-specific symptoms, gets the right tests at the right time in as few visits as possible. By March 2024, the NSS programme will achieve full population coverage across England for non-specific symptom pathways as set out in the 2023/24 NHS Planning Guidance.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/11/2023 11:10:53 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4498 label Biography information for Mr Ranil Jayawardena

1670389

registered interest
date	15/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Commercial Clinical Trials in the UK Review
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps her Department has taken to implement the (a) significant actions under problem statement 6 and (b) other recommendations of the Lord O'Shaughnessy review of commercial clinical trials.
tabling member constituency	North East Hampshire
tabling member printed	Mr Ranil Jayawardena
uin	2192
answer	answer is ministerial correction date of answer 21/11/2023 answer text <p>The Government will soon publish a full response to the Lord O’Shaughnessy independent review into commercial clinical trials.</p><p>The response will include an update on progress and implementation of the initial five headline commitments and foundational actions that the Government made in May 2023 as well as all other recommendations in the review.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 21/11/2023 16:03:12 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4498 label Biography information for Mr Ranil Jayawardena